Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma

Respiratory Medicine

Volumn 118, Issue , 2016, Pages 122-127

  Westerhof, Guus A ^a   de Groot, Jantina C ^b   Amelink, Marijke ^a   de Nijs, Selma B ^a   ten Brinke, Anneke ^b   Weersink, Els J ^a   Bel, Elisabeth H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Adult asthma; Exacerbation; Predictors; Severe asthma; Smokers

Indexed keywords

CORTICOSTEROID; METHACHOLINE;

ADULT; ARTICLE; ASTHMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE EXACERBATION; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; LUNG CAPACITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL COUNT; ONSET AGE; PRIORITY JOURNAL; RESIDUAL VOLUME; RESPIRATORY TRACT ALLERGY; SMOKING CESSATION; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; EOSINOPHIL; EPIDEMIOLOGY; IMMUNOLOGY; INFLAMMATION; METABOLISM; NETHERLANDS; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX; SMOKING;

ADRENAL CORTEX HORMONES; ADULT; ASTHMA; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NETHERLANDS; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84982128195     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.08.006     Document Type: Article

References (37)

1. [1] (GINA), Global Strategy for Asthma Management and Prevention 2014 (Update). 2014, GINA http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2014_Jun11.pdf.
2. [2] Pavord, I.D., Eosinophilic phenotypes of airway disease. Ann. Am. Thorac. Soc. 10:Suppl (2013), S143–S149.
3. [3] Pizzichini, M.M., Pizzichini, E., Clelland, L., et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur. Respir. J. 13:1 (1999), 15–21.
4. [4] Jatakanon, A., Lim, S., Barnes, P.J., Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med. 161:1 (2000), 64–72.
5. [5] Green, R.H., Brightling, C.E., McKenna, S., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 360:9347 (2002), 1715–1721.
6. [6] Jayaram, L., Pizzichini, M.M., Cook, R.J., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 27:3 (2006), 483–494.
7. [7] Pavord, I.D., Korn, S., Howarth, P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 380:9842 (2012), 651–659.
8. [8] Bel, E.H., Wenzel, S.E., Thompson, P.J., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371:13 (2014), 1189–1197.
9. [9] Polosa, R., Thomson, N.C., Smoking and asthma: dangerous liaisons. Eur. Respir. J. 41:3 (2013), 716–726.
10. [10] Amelink, M., de Nijs, S.B., de Groot, J.C., et al. Three phenotypes of adult-onset asthma. Allergy 68:5 (2013), 674–680.
11. [11] Westerhof, G.A., Vollema, E.M., Weersink, E.J., Reinartz, S.M., de Nijs, S.B., Bel, E.H., Predictors for the development of progressive severity in new-onset adult asthma. J. Allergy Clin. Immunol., 134(5), 2014 Nov 1051-6.e2.
12. [12] de Groot, J.C., van Roon, E.N., Storm, H., et al. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. J. Allergy Clin. Immunol. 135:3 (2015), 670–675 e673.
13. [13] Chung, K.F., Wenzel, S.E., Brozek, J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43:2 (2014), 343–373.
14. [14] ten Brinke, A., Sterk, P.J., Masclee, A.A., et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J. 26:5 (2005), 812–818.
15. [15] Kupczyk, M., ten Brinke, A., Sterk, P.J., et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin. Exp. Allergy. 44:2 (2014), 212–221.
16. [16] Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 14:4 (1999), 902–907.
17. [17] Juniper, E.F., Guyatt, G.H., Epstein, R.S., Ferrie, P.J., Jaeschke, R., Hiller, T.K., Evaluation of impairment of health related quality-of-life in asthma - development of A Questionnaire for use in clinical-trials. Thorax. 47:2 (1992), 76–83.
18. [18] Miller, M.R., Hankinson, J., Brusasco, V., et al. Standardisation of spirometry. Eur. Respir. J. 26:2 (2005), 319–338.
19. [19] MacIntyre, N., Crapo, R.O., Viegi, G., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 26:4 (2005), 720–735.
20. [20] Wanger, J., Clausen, J.L., Coates, A., et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 26:3 (2005), 511–522.
21. [21] Sterk, P.J., Fabbri, L.M., Quanjer, P.H., et al. Airway responsiveness – standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults – report working party standardization of lung-function tests european-community for steel and coal - official statement of the european respiratory society. Eur. Respir. J. 6 (1993), 53–83.
22. [22] Dweik, R.A., Boggs, P.B., Erzurum, S.C., et al. An Official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 184:5 (2011), 602–615.
23. [23] Paggiaro, P.L., Chanez, P., Holz, O., et al. Sputum induction. Eur. Respir. J. 37:Suppl. (2002), 3s–8s.
24. [24] Zeiger, R.S., Schatz, M., Li, Q., et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J. Allergy Clin. Immunol. Pract. 2:6 (2014), 741–750.
25. [25] Chipps, B.E., Zeiger, R.S., Borish, L., et al. Key findings and clinical implications from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. J. Allergy Clin. Immunol., 130(2), 2012, 332.
26. [26] Greenberg, S., Liu, N., Kaur, A., et al. The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks. J. Allergy Clin. Immunol. 130:5 (2012), 1071–1077 e1010.
27. [27] Bateman, E.D., Buhl, R., O'Byrne, P.M., et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J. Allergy Clin. Immunol., 135(6), 2015 Jun 1457-64.e4.
28. [28] Hurst, J.R., Vestbo, J., Anzueto, A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363:12 (2010), 1128–1138.
29. [29] Bafadhel, M., McKenna, S., Terry, S., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 184:6 (2011), 662–671.
30. [30] Thomson, N.C., Chaudhuri, R., Heaney, L.G., et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J. Allergy Clin. Immunol. 131:4 (2013), 1008–1016.
31. [31] Lugade, A.A., Bogner, P.N., Thatcher, T.H., Sime, P.J., Phipps, R.P., Thanavala, Y., Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection. J. Immunol. 192:11 (2014), 5226–5235.
32. [32] Venarske, D.L., Busse, W.W., Griffin, M.R., et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. J. Infect. Dis. 193:11 (2006), 1536–1543.
33. [33] Green, B.J., Wiriyachaiporn, S., Grainge, C., et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One., 9(6), 2014, e100645.
34. [34] Barnes, P.J., Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131:3 (2013), 636–645.
35. [35] Nair, P., Aziz-Ur-Rehman, A., Radford, K., Therapeutic implications of 'neutrophilic asthma'. Curr. Opin. Pulm. Med. 21:1 (2015), 33–38.
36. [36] Roche, N., Postma, D.S., Colice, G., et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. Am. J. Respir. Crit. Care Med. 191:8 (2015), 960–964.
37. [37] Brusselle, G.G., Vanderstichele, C., Jordens, P., et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68:4 (2013), 322–329.